Skip to main content
Premium Trial:

Request an Annual Quote

Integrated DNA Technologies Obtains Right to Sell ddRNAi Oligos from Promega

NEW YORK, June 10 (GenomeWeb News) - Integrated DNA Technologies has licensed DNA-directed RNA interference technology from Promega, the company said yesterday.


Under the non-exclusive agreement, IDT can make and sell oligos for use in ddRNAi. The company, based in Coralville, Iowa, is the first oligonucleotide manufacturer in the US to obtain a ddRNAi license from Promega.


Promega, in turn, holds an exclusive license from Benitec that allows it to sell custom ddRNAi-related oligos and related services. The technology is protected in the United States by US patent No. 6,573,099.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.